The antihypertensive effect and tolerability of candesartan cilexetil, a new generation angiotensin II antagonist, in comparison with losartan

Blood Pressure

Volumn 7, Issue 1, 1998, Pages 53-59

  Andersson, Ove K ^a   Neldam, Steen ^b  

^a SAHLGRENSKA UNIVERSITY HOSPITAL   (Sweden)

^b Swedish Danish MC Group   (Denmark)

Author keywords

Angiotensin II antagonist; Candesartan cilexetil; Clinical study; Hypertension; Losartan; Placebo

Indexed keywords

ANGIOTENSIN II ANTAGONIST; CANDESARTAN HEXETIL; LOSARTAN;

ADULT; AGED; ARTICLE; CLINICAL TRIAL; CONTROLLED STUDY; DIASTOLIC BLOOD PRESSURE; DOUBLE BLIND PROCEDURE; DRUG TOLERABILITY; FEMALE; HEADACHE; HEART RATE; HUMAN; HYPERTENSION; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SINGLE BLIND PROCEDURE; VERTIGO;

ADULT; ANGIOTENSIN II; ANTIHYPERTENSIVE AGENTS; BENZIMIDAZOLES; BIPHENYL COMPOUNDS; BLOOD PRESSURE; DOUBLE-BLIND METHOD; FEMALE; HEART RATE; HUMANS; HYPERTENSION; LOSARTAN; MALE; MIDDLE AGED; TETRAZOLES; TREATMENT OUTCOME;

EID: 0031882729     PISSN: 08037051     EISSN: None     Source Type: Journal    
DOI: 10.1080/080370598437574     Document Type: Article

References (19)

1. Wexler, RR, Carini, DJ, Duncia, JV, et al. Rationale for the chemical development of angiotensin II receptor antagonists. Am J Hypertens 1992; 5: S209-20.
2. Goldberg, AI, Dunlay, MC, Sweet, CS. Safety and tolerability of losartan potassium, an angiotensin II receptor antagonist, compared with hydrochlorothiazide, atenolol, felodipine ER, and angiotensin-converting enzyme inhibitors for the treatment of systemic hypertension. Am J Cardiol 1995; 75: 793-5.
3. Arakawa, K, Ogihara, T, Iimura, O, et al. Evaluation of clinical usefulness of TCV-116 (candesartan cilexetil) in patients with essential hypertension - A double-blind, parallel-group comparison study using enalapril maleate as control drug. J Clin Ther Med 1996; 12: 2613-61.
4. Urata, H, Boehm, KD, Philip, A, et al. Cellular localization and regional distribution of an angiotensin II-forming chymase in the heart. J Clin Invest 1993; 91: 1269-81.
5. Kang, PM, Landau, AJ, Eberhardt, RT, Frishman, WH. Angiotensin II receptor antagonists: a new approach to blockade of the renin-angiotensin system. Am Heart J 1994; 127: 1388-1401.
6. Gradman, AH, Arcuri, KE, Goldberg, AI, et al. A randomized, placebo-controlled, double-blind, parallel study of various doses of losartan potassium compared with enalapril maleate in patients with essential hypertension. Hypertension 1995; 25: 1345-50.
7. Ikeda, LS, Harm, SC, Arcuri, KE, Goldberg, AI, Sweet, CS. Comparative antihypertensive effects of losartan 50 mg and losartan 50 mg titrated to 100 mg in patients with essential hypertension. Blood Pressure 1997; 6: 35-43.
8. Kubo, K, Kohara, Y, Imamiya, E, et al. Non-peptide angiotensin II receptor antagonists. Synthesis and biological activity of benzimidazolecarboxylic acids. J Med Chem 1993; 36: 2182-95.
9. 1 receptor. Eur J Pharmacol 1997; 319: 137-46.
10. Elmfeldt, D, George, M, Hübner, R, Olofsson, B. Candesartan cilexetil, a new generation angiotensin II antagonist, provides dose dependent antihypertensive effect. J Hum Hypertens 1997; 11 (Suppl 2): S49-53.
11. O'Brien, E, Mee, F, Atkins, N. An accurate automated device for home blood pressure measurement at last! The Omron HEM-705CP. J Hypertens 1994; 12: 1317-8.
12. Neaton, JD, Grimm Jr, RH, Prineas, RJ, et al. Treatment of mild hypertension study. Final results. JAMA 1993; 270: 713-24.
13. Materson, BJ, Reda, DJ, Cushman, WC, et al. Single-drug therapy for hypertension in men. A comparison of six antihypertensive agents with placebo. N Engl J Med 1993; 328: 914-21.
14. MacMahon, S, Rodgers, A. The effects of antihypertensive treatment on vascular disease: reappraisal of the evidence in 1994. J Vasc Med Biol 1993; 4: 265-71.
15. Conway, J, Coats, A. Value of ambulatory blood pressure monitoring in clinical pharmacology. J Hypertens 1989; 7 (Suppl 3): S29-32.
16. FDC Reports 1988; 50: 9-10.
17. Delacrétaz, E, Nussberger, J, Biollaz, J, Waeber, B, Brunner, HR. Characterization of the angiotensin II receptor antagonist TCV-116 in healthy volunteers. Hypertension 1995; 25: 14-21.
18. Munafo, A, Christen, Y, Nussberger, J, et al. Drug concentration response relationships in normal volunteers after oral administration of losartan, an angiotensin II receptor antagonist. Clin Pharmacol Ther 1992; 51: 513-5.
19. Christen, Y, Waeber, B, Nussberger, J, et al. Oral administration of DuP 753, a specific angiotensin II receptor antagonist, to normal male volunteers: inhibition of pressor response to exogenous angiotensin I and II. Circulation 1991; 83: 1333-42.